Blood sampling: the blood sample will be taken during a planned blood sampling
Study summary
Sickle cell disease (SCD) is an autosomal recessive genetic disorder linked to a single mutation on beta-globin chains. This leads to red blood cell deformation and chronic hemolysis which can result in vaso-occlusive events, anemia and vasculopathy. Pathophysiology is incompletely understood, and beyond red blood cell's abnormalities this involves hemostasis and innate immunity. The aim of our study is to describe the mechanisms of thrombo-inflammation during the vaso-occlusive crisis (VOC) in adults with sickle cell disease.
Eligibility
Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria:
* Patient with sickle cell disease diagnosis, hospitalized in emergency department and/or internal medicine department
* Patient older than 18 years
* Written consent to participate to the study
* Patient with health insurance
* Patient able to receive information about the study
Exclusion Criteria:
* Age \< 18 years
* Non consent to participate to the study
* Women in pregnancy or breastfeeding
* Treatment with aspirin or non steroidal anti inflammatory drug
* Protected patient
* Patient already involved in a study requiring collection of additional biological samples
Primary outcome measure(s)
To evaluate mechanisms of platelet activation in the thrombo-inflammation process during a vaso-occlusive crisis. — First 48h of hospitalization by flow cytometry analysis
To evaluate mechanisms of platelet activation in the thrombo-inflammation process during a vaso-occlusive crisis. — Day 13 (+/- 2 days) by flow cytometry analysis
To evaluate mechanisms of platelet activation in the thrombo-inflammation process during a vaso-occlusive crisis. — At day 60 (+/- 2 days) by flow cytometry analysis
Trial sites (1)
Facility
City
Region
Status
IUCT-Oncopole University Hospital
Toulouse
France
More University Hospital, Toulouse trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
